CGRP

News

Bottle of Qulipta superimposed on image of woman holding head against sun dappled wall

AbbVie charts a new course for CGRPs in menstrual migraine

AbbVie's Qulipta has become the first oral CGRP inhibitor to show efficacy in a phase 3 study involving women with menstrual migraine.

News

Chasing rivals, AbbVie files migraine prevention drug atogep...

AbbVie has submitted its oral CGRP inhibitor atogepant for prevention of both episodic and chronic migraine in the EU as it tries to catch up with main rivals Pfizer/BioHaven and their rece

News

Pfizer upgrades Biohaven alliance to a takeover bid

Not content with a $1.2 billion licensing deal for Biohaven Pharma's oral migrain

News

Pfizer/Biohaven migraine drug rimegepant gets EU green light

Pfizer's $1.2 billion licensing deal with Biohaven for rights to oral migraine drug rimegepant is approaching a payoff after the European Commission approved the drug.

News

Amid crowded migraine market, Lundbeck goes its own way

The market for migraine treatment and prevention has been transformed by the launch of several new drugs targeting CGRP for many sufferers, but Lundbeck thinks there is still room for new a

News

Pfizer strikes $1.2bn licensing deal for Biohaven migraine d...

Pfizer has bolstered its central nervous system (CNS) drugs portfolio with a $1.2 billion deal to claim rights outside the US to Biohaven's Nurtec ODT, an oral therapy for migraine.

AbbVie charts a new course for CGRPs in menstrual migraine

Chasing rivals, AbbVie files migraine prevention drug atogep...

Pfizer upgrades Biohaven alliance to a takeover bid

Pfizer/Biohaven migraine drug rimegepant gets EU green light

Amid crowded migraine market, Lundbeck goes its own way

Pfizer strikes $1.2bn licensing deal for Biohaven migraine d...

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

CGRP

Editor's Picks